Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years.
about
Molecular Mechanisms and Metabolomics of Natural Polyphenols Interfering with Breast Cancer MetastasisNetwork pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients.RAS pathway biomarkers for breast cancer prognosis.Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis.Factors associated with breast cancer mortality after local recurrenceAssociation between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survivalMetastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors.Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration.GATA4 immunolocalization in breast carcinoma as a potent prognostic predictor.Defining the survival benchmark for breast cancer patients with systemic relapseExtracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites.Fe65 Suppresses Breast Cancer Cell Migration and Invasion through Tip60 Mediated Cortactin AcetylationThe Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC).Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine ModelMulti-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective.Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician surveyContrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implicationsChemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.Prognostic Value of EMT-inducing Transcription Factors (EMT-TFs) in Metastatic Breast Cancer: A Systematic Review and Meta-analysis.TACC2 (transforming acidic coiled-coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferationSIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast CancerGlobal radiation oncology waybill.CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance.Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patientsPatterns of statin initiation and continuation in patients with breast or colorectal cancer, towards end-of-life.Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.Genomic Evolution of Breast Cancer Metastasis and Relapse.Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.Etirinotecan pegol for the treatment of breast cancer.Targeting metastasis.Cardiac Complications of HER2-Targeted Therapies in Breast Cancer.A systematic review of psychotherapeutic interventions for women with metastatic breast cancer: Context matters.Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancerCyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.Learning from big data: are we undertreating older women with high-risk breast cancer?A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer.Hexokinase II in breast carcinoma: a potent prognostic factor associated with hypoxia-inducible factor-1α and Ki-67.Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.Monocytes Differentiate to Immune Suppressive Precursors of Metastasis-Associated Macrophages in Mouse Models of Metastatic Breast Cancer.
P2860
Q28076953-1C65A9F5-56F2-4615-87EE-F86FE7882E19Q33688907-B99F8BFD-329D-40F8-806B-0F6E31781781Q33757299-611AB666-1865-4F0D-AD96-3663E49BDBE6Q33761491-C260882D-A869-4318-AD02-8BE90A512C21Q33763899-C26CF099-A568-40F8-A219-891B02C63232Q34240707-63149BA9-2FD4-4FE2-AF0F-434CCAD6C77FQ34253243-CF194864-430D-48F9-927F-FB5F05F0A002Q34706851-29968DB4-C439-4C26-907C-5DAA3D213984Q35051560-F209B8FA-A355-460D-B5C6-E12152973CA1Q35459288-466F37FF-F31C-48B5-84E8-A9E9495D3AE2Q35741584-0A3E4EFF-9897-4817-B6C3-1BEF163258EBQ35844455-7707DB4D-9A62-4AD7-BD30-C97E03BE7D90Q35930745-CE1DDD7F-7DB5-48CE-BABB-BDD172D57B97Q36184480-8F9C5AFA-DD55-4F70-9C86-F46978C5A1CBQ36293907-A7EAD64E-4CAB-48A2-9E91-8A6A34F040ABQ36528355-43C3BC06-7CEF-438B-B3B2-D31787894B81Q36545146-2DEBC48B-991F-4634-A41E-649A4DEB5B5EQ36630732-A995B79D-8BB5-4F8F-8CFA-B099FFD1B7DBQ37030764-07A4CC72-4036-450E-B045-1D356A9F0E6EQ37148953-FA4064E6-017E-447D-B4A3-157B3636F9EBQ37309686-81344A77-2AFE-40AA-9F1A-58DB867BCACFQ37392311-AD63967D-B744-4A96-A52E-19321F4D46BDQ37544330-89106FD8-A064-48FE-881E-D665B27280E3Q37688228-4870E90F-C90B-4803-9F40-7691CEE8F24CQ37736058-9A4C0CF1-F10F-4D19-81FB-FDF3D8F2B6C0Q38269966-AEA7747E-1CC3-4F54-BCA0-0592957F6824Q38623761-EB1DD719-E8D8-4AD6-9CD0-2C93021101E6Q38647605-8AD17E20-37A4-409D-952C-B1792BD3F018Q38735361-31A1CC5A-500B-4349-94DD-C5503931C784Q38786658-B4969E65-9C98-4A7A-A528-CE9596B75DF0Q38791220-CF0CAA02-13D6-4772-A6F1-036C0A3B6264Q38825388-232AD7FE-D1E6-47FE-8B68-0AE3414A71E9Q39185424-9FE0FD18-EDB3-4D01-970F-478E5A6E4970Q39534421-D9CD0B89-4B1B-4C1E-86AA-CA744D4B1DF7Q40951473-4FE5A0FB-4652-4280-96D6-259D92720FA4Q42334187-F6A60AA0-38EC-4FDD-A5AD-AB9FCFE2D2C8Q43787894-DA16D99E-C1C1-4835-B501-049AEB53F547Q47977198-1960A238-481B-4971-B417-A8BDECC7E409Q49517068-DC1F4743-C4D7-483C-8207-3FF79CCACF33Q49539665-4B4F92A9-E08B-407B-94E3-44273C3104B0
P2860
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Survival in patients with meta ...... vement over the past 30 years.
@ast
Survival in patients with meta ...... vement over the past 30 years.
@en
type
label
Survival in patients with meta ...... vement over the past 30 years.
@ast
Survival in patients with meta ...... vement over the past 30 years.
@en
prefLabel
Survival in patients with meta ...... vement over the past 30 years.
@ast
Survival in patients with meta ...... vement over the past 30 years.
@en
P2093
P2860
P356
P1433
P1476
Survival in patients with meta ...... vement over the past 30 years.
@en
P2093
Amye J Tevaarwerk
Bryan P Schneider
John H Fetting
Joseph A Sparano
Kathy D Miller
Lori J Goldstein
Lynne I Wagner
Mary Lou Smith
Nancy Davidson
Robert J Gray
P2860
P304
P356
10.1002/CNCR.27819
P407
P577
2012-10-12T00:00:00Z